Patent intelligence · US
US 8609856
Crystalline forms of Febuxostat
Crystalline forms of Febuxostat
Patent details — US 8609856
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 17, 2013
- Expiration
- Dec 12, 2033
- Applicant
- Teva Pharmaceuticals USA, Inc.
- Claims
- 20
- CPC classes
- A61P, A61P19/06
Quick answer
US 8609856 (Crystalline forms of Febuxostat) is held by Teva Pharmaceuticals USA, Inc.. Status: granted. Granted Dec 17, 2013. Expires Dec 12, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Teva Pharmaceuticals USA, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P19/06
More from Teva Pharmaceuticals USA, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8609856?
US 8609856 (Crystalline forms of Febuxostat) is held by Teva Pharmaceuticals USA, Inc.. Status: granted. Granted Dec 17, 2013. Expires Dec 12, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8609856?
Teva Pharmaceuticals USA, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8609856 expire?
Our index shows an expiration date of Dec 12, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.